Drug Target Review's Dr Raminderpal Singh spoke to our CDSO and Cofounder Dr Layla Hosseini-Gerami about AI-driven approaches to solving toxicity challenges in drug discovery.
“The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues. In a recent conversation with Layla Hosseini-Gerami, Chief Data Science Officer and Co-founder of Ignota Labs, we explored this critical issue, considering how artificial intelligence (AI) and advanced data science approaches may provide solutions.
Ignota Labs specialises in identifying failed drug candidates, resolving their issues and turning them around before selling them back to pharmaceutical companies. As Hosseini-Gerami explains:
“We’re a biotech company that solves the issue of failed drugs by finding failed drugs, fixing them, turning them around and selling them back to Pharma.””
Read more:
Part 1 of 'Fixing failed drugs - AI solutions for toxicity in drug discovery,' can be read in full at Drug Target Review.
Published: 14 July 2025 by Drug Target Review.
